Warning about Xofigo with Zytiga and prednisone or prednisolone in prostate cancer

El acceso al contenido completo es sólo para profesionales sanitarios registrados. Regístrate para leer más

The European Medicines Agency (EMA) has launched an investigation into an increased risk of death and fractures reported in an ongoing clinical trial with the prostate cancer drug Xofigo (radium-223 dichloride).

The clinical trial is examining Xofigo versus placebo, both given in combination wit...